|
1
|
Tanaka Y: Subcutaneous injection of
methotrexate: Advantages in the treatment of rheumatoid arthritis.
Mod Rheumatol. 33:633–639. 2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hoekstra M, van Ede AE, Haagsma CJ, van de
Laar MA, Huizinga TW, Kruijsen MW and Laan RF: Factors associated
with toxicity, final dose, and efficacy of methotrexate in patients
with rheumatoid arthritis. Ann Rheum Dis. 62:423–426.
2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wegrzyn J, Adeleine P and Miossec P:
Better efficacy of methotrexate given by intramuscular injection
than orally in patients with rheumatoid arthritis. Ann Rheum Dis.
63:1232–1234. 2004.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Harigai M, Kaneko Y, Tanaka E, Hirata S,
Kameda H, Kaneko K, Kishimoto M, Kohno M, Kojima M, Kojima T, et
al: 2024 update of the Japan college of rheumatology clinical
practice guidelines for the management of rheumatoid arthritis:
Secondary publication. Mod Rheumatol. 35:387–401. 2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Qiao L, Hu J, Ou D, Liu M, Shi X, Li X, Wu
R, Zhang L, Liu Y, Xiao C, et al: Comparison of the efficacy and
safety of methotrexate injection and methotrexate tablets in active
RA. Rheumatology (Oxford). 64:3426–3433. 2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bujor AM, Janjua S, LaValley MP, Duran J,
Braun J and Felson DT: Comparison of oral versus parenteral
methotrexate in the treatment of rheumatoid arthritis: A
meta-analysis. PLoS One. 14(e0221823)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kameda H, Yamaoka K, Yamanishi Y, Tada M,
Koike R, Nakajima A, Fusama M and Fujii T: Japan College of
Rheumatology guidance for the use of methotrexate in patients with
rheumatoid arthritis: Secondary publication. Mod Rheumatol.
34:1–10. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Braun J, Kästner P, Flaxenberg P, Währisch
J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W,
Pichlmeier U, et al: Comparison of the clinical efficacy and safety
of subcutaneous versus oral administration of methotrexate in
patients with active rheumatoid arthritis: Results of a six-month,
multicenter, randomized, double-blind, controlled, phase IV trial.
Arthritis Rheum. 58:73–81. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Acuña-Rocha VD, Regalado-Ceballos D,
Salcedo-Soto DA, Ramos-Delgado CA, Esquivel-Valerio JA, Hernandez
Galarza IJ, Galarza-Delgado DA and Flores-Alvarado DE: Clinical
characteristics of young-onset versus elderly-onset rheumatoid
arthritis: A systematic review and meta-analysis. Cureus.
16(e74148)2024.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mirza A and Nisar MK: Should all patients
trial subcutaneous methotrexate prior to commencing biologic
therapy? A real world study. Mediterr J Rheumatol. 35:115–122.
2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hayashi K, Sada KE, Asano Y, Asano SH,
Yamamura Y, Ohashi K, Morishita M, Watanabe H, Narazaki M,
Matsumoto Y and Wada J: Risk of higher dose methotrexate for renal
impairment in patients with rheumatoid arthritis. Sci Rep.
10(18715)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Pavy S, Constantin A, Pham T, Gossec L,
Maillefert JF, Cantagrel A, Combe B, Flipo RM, Goupille P, Le Loët
X, et al: Methotrexate therapy for rheumatoid arthritis: Clinical
practice guidelines based on published evidence and expert opinion.
Joint Bone Spine. 73:388–395. 2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tanaka Y, Okuda K, Takeuchi Y, Katayama K,
Haji Y, Yamanishi Y, Tribanek M, Guimbal-Schmolck C and Takeuchi T:
Efficacy and tolerability of subcutaneously administered
methotrexate including dose escalation in long-term treatment of
rheumatoid arthritis in a Japanese population. Mod Rheumatol.
33:680–689. 2023.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Villarreal V, Gutierrez N,
Rodriguez-Linares P, Cardozo M, Rojas-Villarraga A and
Santos-Moreno P: POS1386-HPR effectiveness of subcutaneous
methotrexate in patients with rheumatoid arthritis and its
persistence in the long term. Anna Rheum Dis. 82 (Suppl
1):S1046–S1047. 2023.
|
|
15
|
Moura CS, Schieir O, Valois MF, Thorne C,
Bartlett SJ, Pope JE, Hitchon CA, Boire G, Haraoui B, Hazlewood GS,
et al: Treatment strategies in early rheumatoid arthritis
methotrexate management: Results from a prospective cohort.
Arthritis Care Res (Hoboken). 72:1104–1111. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Dervieux T, Zablocki R and Kremer J: Red
blood cell methotrexate polyglutamates emerge as a function of
dosage intensity and route of administration during pulse
methotrexate therapy in rheumatoid arthritis. Rheumatology
(Oxford). 49:2337–2345. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Stamp LK, Barclay ML, O'Donnell JL, Zhang
M, Drake J, Frampton C and Chapman PT: Effects of changing from
oral to subcutaneous methotrexate on red blood cell methotrexate
polyglutamate concentrations and disease activity in patients with
rheumatoid arthritis. J Rheumatol. 38:2540–2547. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mohamed HJ, Sorich MJ, Kowalski SM,
McKinnon R, Proudman SM, Cleland L and Wiese MD: The role and
utility of measuring red blood cell methotrexate polyglutamate
concentrations in inflammatory arthropathies-a systematic review.
Eur J Clin Pharmacol. 71:411–423. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Hoekstra M, Haagsma C, Neef C, Proost J,
Knuif A and van de Laar M: Bioavailability of higher dose
methotrexate comparing oral and subcutaneous administration in
patients with rheumatoid arthritis. J Rheumatol. 31:645–648.
2004.PubMed/NCBI
|
|
20
|
Schiff MH, Jaffe JS and Freundlich B:
Head-to-head, randomised, crossover study of oral versus
subcutaneous methotrexate in patients with rheumatoid arthritis:
Drug-exposure limitations of oral methotrexate at doses ≥15 mg may
be overcome with subcutaneous administration. Ann Rheum Dis.
73:1549–1551. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Roszkiewicz J, Swacha Z and Smolewska E:
Prefilled pen versus prefilled syringe: A pilot study evaluating
two different methods of methotrexate subcutaneous injection in
patients with JIA. Pediatr Rheumatol Online J.
18(64)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Demary W, Schwenke H, Rockwitz K, Kästner
P, Liebhaber A, Schoo U, Hübner G, Pichlmeier U, Guimbal-Schmolck C
and Müller-Ladner U: Subcutaneously administered methotrexate for
rheumatoid arthritis, by prefilled syringes versus prefilled pens:
Patient preference and comparison of the self-injection experience.
Patient Prefer Adherence. 8:1061–1071. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pachon JA, Kivitz AJ, Heuer KU and
Pichlmeier U: Assessing usability, label comprehension, pen
robustness and pharmacokinetics of a self-administered prefilled
autoinjector pen of methotrexate in patients with rheumatoid
arthritis. SAGE Open Med. 2(2050312114564241)2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hudry C, Lebrun A, Moura B, Zinovieva E,
Backers O and Herman-Demars H: Evaluation of usability and
acceptance of a new autoinjector intended for methotrexate
subcutaneous self-administration in the management of rheumatoid
arthritis. Rheumatol Ther. 4:183–194. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Saraux A, Hudry C, Zinovieva E and
Herman-Demars H: Self-I Investigators group. Use of auto-injector
for methotrexate subcutaneous self-injections: High satisfaction
level and good compliance in SELF-I study, a randomized,
open-label, parallel group study. Rheumatol Ther. 6:47–60.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yoo DH, Hrycaj P, Miranda P, Ramiterre E,
Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi
M, Gutierrez-Ureña S, et al: A randomised, double-blind,
parallel-group study to demonstrate equivalence in efficacy and
safety of CT-P13 compared with innovator infliximab when
coadministered with methotrexate in patients with active rheumatoid
arthritis: The PLANETRA study. Ann Rheum Dis. 72:1613–1620.
2013.PubMed/NCBI View Article : Google Scholar
|
